LSU Chancellor James Dalton was featured in a New York Times story Monday that highlighted his work developing a drug that’s become controversial for its unauthorized use by athletes.

The drug, known as ostarine, was developed around 25 years ago by a team including Dalton when he was an associate professor at University of Tennessee in Memphis.

Dalton’s background is in drug science, and he has more than 500 patents to his name internationally, according to The New York Times.

Ostarine’s original purpose, The New York Times said, was to produce the effects of testosterone or anabolic steroids without the undesirable side effects. The hope was that it could be used, for example, to build muscle mass for patients with cancer or osteoporosis or the elderly.

Decades later, the drug still hasn’t been approved for human use. It has, however, been detected in athletes using it for doping.

The World Anti-Doping Agency added Ostarine to its list of banned substances, and a number of Olympic athletes — and even some competitive horses — have been sanctioned for using it.

Dalton’s work related to the drug now is entirely related to preventing it from being used for reasons he never intended. He’s advised the U.S. Anti-Doping Agency on Ostarine cases and chairs the United States Anti-Doping Agency’s scientific advisory board for Partnership for Clean Competition.

“I spend more time now trying to stop people from using it than trying to get people to use it,” Dalton told The New York Times. “That wasn’t what I ever set out to do with this.”

Dalton was named the LSU executive president and chancellor in November. The position was revived when the role of LSU president was split into system president (now Wade Rousse) and chancellor of the Baton Rouge campus.